Regeneron Reports Longer-Term P-III (C-POST) Trial Data of Adjuvant Libtayo (Cemiplimab) for High-Risk Cutaneous Squamous Cell Carcinoma at ESMO 2026

Shots: Regeneron reported ~4yr follow-up data from the P-III (C-POST) trial of Libtayo (cemiplimab) vs PBO as adjuvant treatment in pts (n=415) with CSCC at high risk of recurrence after surgery & radiation; presented as a late-breaking rapid oral at ESMO 2026 At a median follow-up of 44mos, Libtayo showed a 37% reduction in risk of death (HR=0.63; 95% CI: 0.36-1.11), up from 22% at 30mos & 14% at 24mos, despite 88% of recurrent PBO pts crossing over to Libtayo; DFS benefit was sustained Exploratory ctDNA analysis showed improved DFS regardless of baseline MRD status (MRD-negative HR=0.45; MRD-positive HR=0.24) Ref: Regeneron  |   Image: Regeneron  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Regeneron Reports Longer-Term P-III (C-POST) Trial Data of Adjuvant Libtayo (Cemiplimab) for High-Risk Cutaneous Squamous Cell Carcinoma at ESMO 2026 appeared first on PharmaShots.